SCHEMBL2067599

SCHEMBL2067599

CC(=O)NC1=CC=CN[C]1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
PTK2 Q05397 1/20 0.33
TP53 P04637 1/20 0.33
HIF1A Q16665 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
HSD17B10 Q99714 3/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NAPRT Q6XQN6 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
LMNA P02545 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067657 0.73 KMT2A (0.41) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL8397828 0.61 HSD17B10 (0.32) ALDH1A1SMN1; SMN2HSD17B10GAAPKM
SCHEMBL21975125 0.59 SMN1; SMN2 (0.38) ALDH1A1PTK2TP53HIF1ASMN1; SMN2
SCHEMBL11281004 0.59 TDP1 (0.45) ALDH1A1PTK2SMN1; SMN2HSD17B10GAA
SCHEMBL2067996 0.58
SCHEMBL4412558 0.58 SMN1; SMN2 (0.46) ALDH1A1PTK2TP53HIF1ASMN1; SMN2
SCHEMBL24268591 0.58 MEN1 (0.33) ALDH1A1PTK2SMN1; SMN2MEN1KMT2A
SCHEMBL15426748 0.58 TDP1 (0.44) ALDH1A1PTK2SMN1; SMN2HSD17B10GAA
SCHEMBL19450903 0.58 PTK2 (0.37) ALDH1A1PTK2SMN1; SMN2HSD17B10GAA
SCHEMBL22203518 0.58 PTK2 (0.37) ALDH1A1PTK2SMN1; SMN2HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ALDH1A1 2405/4885PTK2 413/4885TP53 3398/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ALDH1A1 2405/4885PTK2 413/4885TP53 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.